The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 1, Pages 217
Publisher
MDPI AG
Online
2022-01-04
DOI
10.3390/cancers14010217
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
- (2021) Jingru Yu et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer
- (2021) Yoshihiko Tasaki et al. CANCER RESEARCH
- A Review of the Diagnosis and Management of Premalignant Pancreatic Cystic Lesions
- (2021) Margaret G. Keane et al. Journal of Clinical Medicine
- Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors
- (2021) Jun Ushio et al. Diagnostics
- A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine‐based chemotherapy in patients with advanced solid tumors
- (2021) Christos Fountzilas et al. INTERNATIONAL JOURNAL OF CANCER
- Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker
- (2021) Fernanda G. Kugeratski et al. NATURE CELL BIOLOGY
- Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis
- (2020) Labrinus van Manen et al. BIOMARKERS
- Diagnostic value of various liquid biopsy methods for pancreatic cancer
- (2020) Yuzhou Zhu et al. MEDICINE
- New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
- (2020) Ritu Raj Singh et al. DRUGS
- Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer
- (2020) Marina Hodolic et al. NUCLEAR MEDICINE COMMUNICATIONS
- A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma
- (2020) Rocio I. R. Macias et al. Cancers
- Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
- (2020) Valeria Merz et al. CLINICAL CANCER RESEARCH
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
- (2020) M.L. Johnson et al. EUROPEAN JOURNAL OF CANCER
- Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer
- (2020) Junjie Huang et al. GASTROENTEROLOGY
- DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
- (2020) Lukas Perkhofer et al. GUT
- Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
- (2020) Yunzhen Qian et al. Journal of Hematology & Oncology
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA
- (2020) Gulfem D. Guler et al. Nature Communications
- Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
- (2020) Yizhi Wang et al. Frontiers in Oncology
- Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection
- (2020) Johannes F. Fahrmann et al. GASTROENTEROLOGY
- Genome-Wide Analysis of Cell-Free DNA Methylation Profiling for the Early Diagnosis of Pancreatic Cancer
- (2020) Shengyue Li et al. Frontiers in Genetics
- Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing
- (2020) Manoj Amrutkar et al. Cancers
- Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma
- (2019) Raghuwansh P. Sah et al. GASTROENTEROLOGY
- CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection
- (2019) Jiarui Li et al. PANCREATOLOGY
- Postoperative surveillance of pancreatic cancer patients
- (2019) L.A. Daamen et al. EJSO
- Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer
- (2019) Yuan Fang et al. EXPERIMENTAL CELL RESEARCH
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retooling a Blood-based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer
- (2019) Christian Lohrmann et al. CLINICAL CANCER RESEARCH
- Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy
- (2019) Deirdré Kruger et al. PLoS One
- Genome-Wide Profiling of Prognostic Alternative Splicing Pattern in Pancreatic Cancer
- (2019) Min Yu et al. Frontiers in Oncology
- From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
- (2019) Christopher Nevala-Plagemann et al. Nature Reviews Clinical Oncology
- Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
- (2019) Max M. Wattenberg et al. BRITISH JOURNAL OF CANCER
- Cell-free microRNAs as Non-invasive Diagnostic and Prognostic Biomarkers in Pancreatic Cancer
- (2019) Natalia A. Gablo et al. CURRENT GENOMICS
- Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers’ Discovery
- (2019) Mariarita Brancaccio et al. Genes
- Metabolic Alterations in Pancreatic Cancer Progression
- (2019) Enza Vernucci et al. Cancers
- Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma
- (2018) Vincent P. Groot et al. ANNALS OF SURGERY
- CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time
- (2018) Caroline J. Rieser et al. ANNALS OF SURGICAL ONCOLOGY
- Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
- (2018) N. O. Elander et al. BRITISH JOURNAL OF CANCER
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
- (2018) Jason D. Merker et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer
- (2018) Lois A. Daamen et al. HPB
- NRG1 Fusions in KRAS Wild-type Pancreatic Cancer
- (2018) Christoph Heining et al. Cancer Discovery
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer
- (2018) Guopei Luo et al. PANCREATOLOGY
- Precursor Lesions of Pancreatic Cancer
- (2018) Joo Y. Kim et al. Oncology Research and Treatment
- Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions
- (2018) Bing Ren et al. AMERICAN JOURNAL OF PATHOLOGY
- Total Serum Cholesterol and Pancreatic Cancer: A Nested Case–Control Study
- (2018) William Chang-Yuen Chen et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer
- (2018) Tatsuya Kitagawa et al. Molecular Oncology
- Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-Analysis
- (2018) Haibo Xing et al. Gastroenterology Research and Practice
- Hypermutation In Pancreatic Cancer
- (2017) Jeremy L. Humphris et al. GASTROENTEROLOGY
- Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
- (2017) Julia Mayerle et al. GUT
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
- (2017) Angela Chou et al. GUT
- A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer
- (2017) Seetharaman Balasenthil et al. JNCI-Journal of the National Cancer Institute
- Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
- (2017) Aatur D. Singhi et al. Journal of the National Comprehensive Cancer Network
- Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas
- (2017) Masao Tanaka et al. PANCREATOLOGY
- The Sendai and Fukuoka consensus criteria for the management of branch duct IPMN - A meta-analysis on their accuracy
- (2017) Max Heckler et al. PANCREATOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers
- (2017) Jungsun Kim et al. Science Translational Medicine
- Current and future biomarkers for pancreatic adenocarcinoma
- (2017) Sven H Loosen et al. TUMOR BIOLOGY
- A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer
- (2017) Seetharaman Balasenthil et al. JNCI-Journal of the National Cancer Institute
- Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
- (2016) Steffen Ormanns et al. BRITISH JOURNAL OF CANCER
- Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas
- (2016) Andreas W. Berger et al. GASTROENTEROLOGY
- MicroRNA in pancreatic cancer
- (2016) Keiichi Yonemori et al. JOURNAL OF HUMAN GENETICS
- SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts
- (2016) H. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
- (2016) Francesca Riva et al. Molecular Oncology
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy
- (2016) Reiko Yamada et al. PANCREAS
- Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping
- (2016) Guopei Luo et al. PANCREATOLOGY
- Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer
- (2016) Erina Takai et al. WORLD JOURNAL OF GASTROENTEROLOGY
- KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
- (2016) Daniel Zeitouni et al. Cancers
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- Integrative analysis of multi-omics data for identifying multi-markers for diagnosing pancreatic cancer
- (2015) Min-Seok Kwon et al. BMC GENOMICS
- SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
- (2015) M. Hidalgo et al. CLINICAL CANCER RESEARCH
- Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
- (2015) Kentaro Minami et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
- (2015) Michela Capello et al. JNCI-Journal of the National Cancer Institute
- Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
- (2015) Sonia A. Melo et al. NATURE
- SPARC
- (2015) Juan Vaz et al. PANCREAS
- Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
- (2015) Mark Sausen et al. Nature Communications
- Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
- (2015) Michela Capello et al. JNCI-Journal of the National Cancer Institute
- Salivary MicroRNA in Pancreatic Cancer Patients
- (2015) Marine Humeau et al. PLoS One
- SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study
- (2014) M. Sinn et al. ANNALS OF ONCOLOGY
- ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance
- (2014) J. D. Kuhlmann et al. CLINICAL CHEMISTRY
- Risk factors for pancreatic cancer: a summary review of meta-analytical studies
- (2014) P. Maisonneuve et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer
- (2014) Nicolai A. Schultz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prediagnostic Serum Biomarkers as Early Detection Tools for Pancreatic Cancer in a Large Prospective Cohort Study
- (2014) Brian M. Nolen et al. PLoS One
- MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer
- (2014) Emily P. Slater et al. Translational Oncology
- Recent studies of 5-fluorouracil resistance in pancreatic cancer
- (2014) Wei-Bin Wang WORLD JOURNAL OF GASTROENTEROLOGY
- Alternative Splice Variants, a New Class of Protein Cancer Biomarker Candidates: Findings in Pancreatic Cancer and Breast Cancer with Systems Biology Implications
- (2013) Gilbert S. Omenn et al. DISEASE MARKERS
- Hyperglycemia, Insulin Resistance, Impaired Pancreatic β-Cell Function, and Risk of Pancreatic Cancer
- (2013) Brian M. Wolpin et al. JNCI-Journal of the National Cancer Institute
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase
- (2013) N Weizman et al. ONCOGENE
- A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers
- (2013) Christina H. Wei et al. PANCREAS
- MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm
- (2013) Yue Xue et al. Cancer Genetics
- The prognostic and predictive value of serum CA19.9 in pancreatic cancer
- (2012) J. L. Humphris et al. ANNALS OF ONCOLOGY
- MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
- (2012) Marilena V. Iorio et al. EMBO Molecular Medicine
- Oxaliplatin: a review in the era of molecularly targeted therapy
- (2011) T. Alcindor et al. Current Oncology
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- Cystic precursors to invasive pancreatic cancer
- (2011) Hanno Matthaei et al. Nature Reviews Gastroenterology & Hepatology
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anthropometric Measures, Body Mass Index, and Pancreatic Cancer
- (2010) Alan A. Arslan ARCHIVES OF INTERNAL MEDICINE
- MicroRNA miR-155 is a biomarker of early pancreatic neoplasia
- (2010) Nils Habbe et al. CANCER BIOLOGY & THERAPY
- Risk of pancreatic cancer by alcohol dose, duration, and pattern of consumption, including binge drinking: a population-based study
- (2010) Samir Gupta et al. CANCER CAUSES & CONTROL
- Plectin-1 as a Novel Biomarker for Pancreatic Cancer
- (2010) D. Bausch et al. CLINICAL CANCER RESEARCH
- Drug Efflux Transporter Multidrug Resistance-Associated Protein 5 Affects Sensitivity of Pancreatic Cancer Cell Lines to the Nucleoside Anticancer Drug 5-Fluorouracil
- (2010) P. K. Nambaru et al. DRUG METABOLISM AND DISPOSITION
- Soluble iC3b as an Early Marker for Pancreatic Adenocarcinoma Is Superior to CA19.9 and Radiology
- (2010) Angela Märten et al. JOURNAL OF IMMUNOTHERAPY
- Aberrant MicroRNA-155 Expression Is an Early Event in the Multistep Progression of Pancreatic Adenocarcinoma
- (2010) Ji Kon Ryu et al. PANCREATOLOGY
- CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
- (2009) H S Wasan et al. BRITISH JOURNAL OF CANCER
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started